The International Generic and Biosimilar medicines Association (IGBA) welcomes the adoption of the WHO Pandemic Agreement at the 78th World Health Assembly in May 2025. This landmark accord represents a critical step toward strengthening global preparedness and ensuring equitable access to essential health products in future pandemics.
The IGBA urgently calls for global collaboration among stakeholders to protect the balance between innovation and access to medicines. A thriving off-patent sector is not a threat to innovation — it is essential to its continuation and sustainability.
The International Generic and Biosimilar medicines Association (IGBA), being the global voice of generic and biosimilar medicines industries, calls for G7 countries to consider health and access to health as a priority in its upcoming discussions, to be held in Alberta, Canada.
- IGBA Welcomes ICH New Topic for Harmonisation: Framework for Determining Utility of Comparative Efficacy Studies in Biosimilar Development Programs (May 2025)
- IGBA Submission to the Request for Public Comments on Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients (May 2025)
- IGBA Joins the Coalition for Access to NCD Medicines and Products (May 2025)
- IGBA Statement on trade barriers and their impact on healthcare systems and patients’ health (March 2025)
